Optain Health Scales Across U.S. Health Systems as Strategic Investment Fuels Next Phase of Growth

Health systems are rolling Optain out across more sites and affiliated networks, as new and existing investors back retinal screening built for frontline care

NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Optain Health, a healthcare technology company applying robotic retinal imaging, teleophthalmology, and artificial intelligence (AI)* to retinal screening in frontline care, today announced accelerating adoption of its screening solution across U.S. health systems, alongside strategic investment from new and existing investors to scale its next phase of growth.

Diabetic retinopathy (DR) is the leading and growing cause of vision loss in working-age adults worldwide, according to a 2025 study. Yet much of this vision loss can be prevented through early detection and timely treatment, according to the National Eye Institute. The CDC estimates that 40 million Americans have diabetes, and only about half receive an annual eye exam.

Primary care is well placed to close this gap, but retinal screening in frontline settings has historically been held back by technology unsuited to primary care, workflows that don't fit busy clinics, and reliance on specialist referrals. Optain was built to solve these challenges, delivering retinal screening that frontline teams will actually use.

Optain's approach is defined by three core elements:

• Designed for frontline care: Built with empathy for primary care workflows, Optain's fast, dilation-free screening fits into routine visits, making it simple for clinical teams to adopt.
• A full-stack solution: Optain brings together its portable robotic retinal camera, imaging software, and teleophthalmology reading service in one end-to-end solution.
• Clinical and enterprise value: Optain's comprehensive retinal screening looks beyond DR alone and is built to deliver return for health systems.

Global scale, growing U.S. impact: Optain supports tens of thousands of retinal screenings globally each month. In the 12 months since its U.S. commercial launch, Optain has partnered with leading U.S. health systems and physician networks that together deliver nearly 5% of the nation's hospital and physician care. Partners have expanded Optain to additional sites and affiliated networks, and U.S. screening volumes have grown by an average of 51% month over month. Nearly one in five people screened had a finding identified for clinical follow-up.

"Our mission is to make retinal screening simple, accessible, and standard in frontline care," said Jeff Dunkel, CEO of Optain Health. "A year after our U.S. commercial launch, health systems aren't just adopting Optain. They're expanding it across their networks. That tells us our end-to-end solution fits the realities of frontline care. Most importantly, it means more patients are being screened and connected to the care they need."

Ryan Graham, Vice President of Practice Operations & Value-Based Care at Privia Health, said: "Optain feels like it is built for the future. There are a lot of features constantly being looked at with regular software updates. We feel good about the [Optain] technology and the future of it. What's stood out to us is how well Optain has kept up with our roll-out plans, and how quickly our teams have embraced it. This is a long-term investment and not just something we are chasing for a one-year program."

Strategic investment to accelerate deployment: Optain has raised strategic financing to scale its U.S. enterprise footprint, speed up health system deployments, and bring screening to more patients. The round brings in new strategic investor Morningside, along with senior leaders from other major U.S. health systems. Nearly all existing investors returned, including Insight Partners and leading U.S. health systems that invested previously. They were joined by the UniQuest Extension Fund, which supports Optain's growth in Australia.

Looking ahead, Optain sees its growing frontline footprint as the foundation for oculomics, the emerging field that uses the eye as a window into whole-body health. Building on more than a decade of oculomics research by its team, Optain plans to bring to market new retinal imaging tests that support earlier detection of broader systemic health conditions.

"A retinal image holds far more information than we've traditionally used, but that insight only matters if screening happens," said Dr. Zachary Tan, President of Optain Health. "Frontline care lets us meet patients where they are, at the point where chronic conditions are first detected. As our footprint grows, so does our opportunity to unlock what the eye can tell us about a patient's overall health - shifting care from reactive, break-fix to proactive, predict-and-prevent healthcare. We are grateful to our partners for their continued confidence as we build toward that future."

*Optain Health utilizes teleophthalmology services in the U.S. AI-based grading software is not currently available in the U.S.

About Optain Health
Optain Health is on a mission to make retinal screening simple, accessible and standard in frontline care. Its portable robotic retinal camera, AI and teleophthalmology service* give clinicians a screening tool that is easy to use, delivers clinically valuable results and helps close the care gap in primary care. In 2025, Optain acquired EyePACS, the largest teleophthalmology network in the U.S., to deliver a complete end-to-end screening solution. Opening eyes to better health.

Learn more at optainhealth.com/us and follow us on LinkedIn.

Forward-Looking Statements
This press release includes forward-looking statements concerning future events. These statements involve risks and uncertainties, and actual results may differ from those expressed or implied. Factors beyond the control of Optain Health and its affiliates may affect future performance. Optain Health and its affiliates do not commit to updating forward-looking statements in light of future events or changes in expectations.

Media inquiries
Kara Spak
[email protected] 

SOURCE Optain Health